Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 8,509 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Group Clear all
Completed Phase 2 Interventional Results available

BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

NCT03193398
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BTRX-246040 oral capsule(s), Placebo oral capsule(s)
Drug
Lead sponsor
BlackThorn Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Cerritos, California • Garden Grove, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quantifying and Developing Countermeasures for the Effect of Fatigue-Related Stressors on Automation Use and Trust During Robotic Supervisory Control

NCT02755493
View directory record Official record
Conditions
Sleep Deprivation
Interventions
Sleep deprivation
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

NCT01488929
View directory record Official record
Conditions
Schizophrenia, Negative Symptoms, Cognitive Dysfunction
Interventions
TC-5619, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Garden Grove, California • Glendale, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT02283853
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Interferon β-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

NCT01376557
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
75 mg LX4211, 200 mg LX4211, 400 mg LX4211, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
56
States / cities
Anaheim, California • Carmichael, California • Greenbrae, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT00384930
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greenwood, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APD356 in the Treatment of Obesity

NCT00104507
View directory record Official record
Conditions
Obesity
Interventions
APD356
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 23, 2026, 4:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ventilatory Physiology in Children at Risk for Anxiety

NCT00101777
View directory record Official record
Conditions
Anxiety, Panic Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Not applicable Interventional

Cross-Education for Chronic Ankle Instability

NCT06401681
View directory record Official record
Conditions
Balance Training Group, Control Group
Interventions
Balance training
Other
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Results available

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

NCT00807937
View directory record Official record
Conditions
Anxiety Disorders
Interventions
AZD7325, Lorazepam, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
51
States / cities
Mesa, Arizona • Little Rock, Arkansas • Carson, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2010 · Synced Oct 23, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

NCT05297045
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RGT001-075, Placebo
Drug · Other
Lead sponsor
Regor Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 23, 2026, 4:17 AM EDT
Active, not recruiting Phase 4 Interventional

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

NCT06101095
View directory record Official record
Conditions
Eosinophilic Oesophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.

NCT02624557
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Alpelisib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
4
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 3 Interventional

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

NCT00147719
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Colesevelam hydrochloride
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
46
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Carmichael, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 4 Interventional Results available

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

NCT01302067
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine 8mg, Fesoterodine 4mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
165
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 130 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

NCT02678000
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
LHW090, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Anaheim, California • Lakewood, Colorado • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2 Interventional

A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED

NCT00127400
View directory record Official record
Conditions
Anger, Intermittent Explosive Disorder
Interventions
anger management therapy
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 23, 2026, 4:17 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

NCT07795164
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions
Pemvidutide, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
9
States / cities
North Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Not applicable Interventional

Non-invasive Spinal Stimulation as an Adjuvant Therapy for Trunk Control After Pediatric SCI

NCT05091463
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Biostim-5/Neostim transcutaneous spinal stimulator
Device
Lead sponsor
University of Louisville
Other
Eligibility
3 Years to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

NCT01650545
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions
Liposomal aerosol cyclosporine, standard immune suppression, oral
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Protein and Fiber at Breakfast on Appetite, Blood Sugar, and Cholesterol

NCT02169245
View directory record Official record
Conditions
Brain Activity, Appetite, Ingestive Behavior, Glucose Control, Cholesterol
Interventions
Dietary control of protein and fiber intake at breakfast
Other
Lead sponsor
Purdue University
Other
Eligibility
21 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
West Lafayete, Indiana • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Not applicable Interventional Results available

Impact of a Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control

NCT01495975
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes Transitions Tool Kit
Other
Lead sponsor
Deborah Wexler, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 23, 2026, 4:17 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension

NCT07661329
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
Interventions
Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®)
Drug
Lead sponsor
YS Life Science Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Beverly Hills, California • Inglewood, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 4:17 AM EDT
Enrolling by invitation Not applicable Interventional

Impact of Integrated Pet Care on Glycemic Control and Diabetes Responsibility

NCT06598345
View directory record Official record
Conditions
Type 1 Diabetes Mellitis
Interventions
Routine Pet Fish Care, Collaborative Communication
Behavioral
Lead sponsor
Duke University
Other
Eligibility
10 Years to 13 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 4:17 AM EDT